Welcome to the ATTD 2022 Interactive Program
The conference will officially run on Central European Summer Time (UTC+2) - Barcelona Time
To convert the conference times to your local time Click Here
Is type 1 diabetes just one disease? Lessons in heterogeneity
Can we arrest type 1 diabetes?
Abstract
Abstract Body
After 100 years of insulin therapy, our insights in the pathogenesis of type 1 diabetes (T1D) have evolved and using the combination of genetic risk and presence of autoantibodies in the blood has allowed us to progress in the prediction of risk. Consortia worldwide are exploring the value of novel biomarkers and evaluate interventions targeting arresting progression of beta-cell destruction in people with newly diagnosed T1D or in those at risk of T1D. In Europe, the IMI2-funded projects INNODIA and INNODIA HARVEST focus on novel biomarker discovery and the consortium is executing 4 clinical trials in people with newly diagnosed T1D. An overview of activities, as well as the evolution of novel therapies for prevention and arrest of T1D will be discussed.